Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mukherjee, Som
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection	Active, not recruiting	2	200	Canada	Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin	Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation	Prostate Cancer	12/24	12/25
SCHOLAR-2, NCT04680442: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction	Recruiting	2	130	Canada, RoW	Trastuzumab, Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti, Pertuzumab, Perjeta, Trastuzumab emtansine, Kadcyla,	Population Health Research Institute	Breast Cancer, Heart Failure	01/25	06/25
IMPACT, NCT06323707: The Implementation-Effectiveness Trial	Recruiting	2	129	Canada	Exercise, Self-management e-module	McMaster University, Canadian Cancer Society (CCS), Hamilton Health Sciences Corporation, Niagara Health System	Cancer	03/27	03/27
PET MUSE, NCT02462239: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging	Completed	N/A	292	Canada	Whole-body FDG PET-CT, PET-CT imaging	Ontario Clinical Oncology Group (OCOG), Cancer Care Ontario	Muscle-invasive Bladder Cancer	03/24	11/24